Zoetis Inc

ZTS

150.608USD

+1.188+0.79%

Market hours （ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

11 / 177

Overall Ranking

90 / 4730

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 20 analysts

Buy

Current Rating

191.789

Target Price

+28.36%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. It is engaged in commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 17.60.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 32.66%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 32.66%.

Undervalued

The company’s latest PE is 25.68, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 434.35M shares, decreasing 0.36% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 41.69M shares of this stock.

The company's current financial score is 7.77, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 2.22B, representing a year-over-year increase of 1.37%, while its net profit experienced a year-over-year increase of 5.34%.

Score

Industry at a Glance

Previous score

7.77

Change

0



Financials

8.69

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.21

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.38

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

8.00

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 4.80, which is higher than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is 26.70, which is 37.08% below the recent high of 36.61 and -21.56% above the recent low of 32.46.

Score

Industry at a Glance

Previous score

4.80

Change

-0.33

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 11/177

No Data

The company’s current earnings forecast score is 7.90, which is lower than the Pharmaceuticals industry's average of 7.96. The average price target for Zoetis Inc is 197.50, with a high of 230.00 and a low of 153.00.

Score

Industry at a Glance

Previous score

7.90

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 8.82, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 162.48 and the support level at 146.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.73

Change

-0.13

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-10

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 98.00%, representing a quarter-over-quarter increase of 0.91%. The largest institutional shareholder is The Vanguard, holding a total of 41.69M shares, representing 9.41% of shares outstanding, with 3.08% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

41.36M

+0.46%

BlackRock Institutional Trust Company, N.A.

23.15M

+0.91%

State Street Global Advisors (US)

19.80M

-0.23%

State Farm Insurance Companies

16.88M

-0.71%

Geode Capital Management, L.L.C.

10.99M

+3.47%

Wellington Management Company, LLP

6.07M

-12.84%

Polen Capital Management, LLC

8.80M

+17.55%

Wells Fargo Advisors

6.01M

+5.97%

Norges Bank Investment Management (NBIM)

5.06M

+1.05%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.53, which is higher than the Pharmaceuticals industry's average of 3.51. The company's beta value is 0.88. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Zoetis Inc

ZTS

7.07 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.67 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.56 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.41 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BridgeBio Pharma Inc

BBIO

7.33 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Biogen Inc

BIIB

7.29 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.